Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
The GLP-1 shortages are over. What happens next?
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy According to Hedge Funds?
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
The Pharma Letter3d
Semaglutide and tirzepatide potential to transform type 1 diabetes treatment
A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and ...
Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says
"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce said at the ...
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.